Compare American Water Works Company Inc (AWK) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Water Works Company Inc vs Regeneron Pharmaceuticals Inc — how do they compare? American Water Works Company Inc trades at $131.69 (market cap $25.69B), while Regeneron Pharmaceuticals Inc trades at $653.1 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.7× American Water Works Company Inc's market cap, and American Water Works Company Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| AWK | REGN | |
|---|---|---|
Market Cap | $25.69B | $68.79B |
Sector | Utilities | Health |
52-Week High | $147.00 | $812.27 |
52-Week Low | $121.13 | $542.52 |
Enterprise Value | $41.25B | $62.74B |
Dividend Yield | 2.72% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Water Works (AWK) trades at $131.53, up 0.64% with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth from $3.8B in 2022 to $5.14B in 2025, maintaining net margins above 21%. Recent earnings show mixed results with a Q3 2025 beat but Q1 2026 miss, while the company continues infrastructure investments and community initiatives.
AWK presents a stable utility investment with moderate upside to the $137 consensus target. Key risks include regulatory approvals for rate increases and high capital expenditures. Analyst sentiment is balanced with 47% buy ratings, though recent earnings misses warrant caution ahead of Q2 2026 results on July 29, 2026.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
